Suscribirse

Safety and effectiveness of combined scoring balloon and paclitaxel-coated balloon angioplasty for stenosis in the hemodialysis access circuit - 02/01/19

Doi : 10.1016/j.diii.2018.05.014 
J. Zheng a, J. Cui b, J. Meiyan Qing c, Z. Irani d,
a Department of Radiology, Shengjing Hospital of China Medical University, 110004 Shenyang, China 
b Division of Nephrology, Department of Medicine, Massachusetts General Hospital, 02114 Boston, Massachusetts, United State of America 
c Montefiore Medical Center Radiology Department, 111E, 210th, street Bronx, 10467 New York, United State of America 
d Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital, 55, Fruit street, GRB 298, 02114 Boston, Massachusetts, United State of America 

Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Purpose

To evaluate the safety and effectiveness of combined scoring balloon (SB) and paclitaxel-coated balloon (PCB) angioplasty for stenosis in the dysfunctional hemodialysis access circuit.

Material and methods

Patients were referred from outpatient dialysis centers by their nephrologists because of dysfunctional dialysis access circuit. Fistulogram/graftogram was performed by experienced interventional radiologists. Those with in-stent stenosis, stent edge stenosis or vessel diameter at the culprit segment larger than 6mm were excluded. Angioplasty of the stenotic segment was performed with SB and followed by PCB. All study outcomes were defined according to the Society of Interventional Radiology technology assessment committee reporting standards for percutaneous interventional procedures in dialysis access circuit.

Results

A total of 23 patients received combined SB/PCB angioplasty for stenosis of hemodialysis access circuit which included 15 fistulas and 8 grafts. There were 10 men and 13 women with a mean age of 63.3±2.7 (SD) years (range: 37–85years). The technical success and clinical success rates were both 100%. There were no complications during or after the procedures. The target lesion primary patency rates at 3, 6 and 12months were 91.3%, 69.6%, and 45.2%, respectively and the estimated median target lesion restenosis (TLR) free duration was 11.0months (95% confidence interval [CI]: 5.1–16.9months). In patients with a recurrent stenosis, the median TLR-free duration of combined angioplasty was significantly higher than that of prior angioplasty with plain balloon (10.2months [95% CI: 6.4–14.0months] vs. 4.2months [95%CI: 2.1–6.4months]) (P=0.047). The mean TLR-free duration was significantly higher in patients with a juxta-anastomotic stenosis than those with non-juxta-anastomotic lesion (21.3months [95% CI: 14.7–28.0months] vs. 8.2months [95% CI: 5.1–11.4months]) (P=0.004).

Conclusion

Combined SB/PCB angioplasty is safe and effective for the hemodialysis access stenosis.

El texto completo de este artículo está disponible en PDF.

Keywords : Angioplasty, Scoring balloon, Paclitaxel-coated balloon, Hemodialysis access circuit, Vascular stenosis


Esquema


© 2018  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 100 - N° 1

P. 31-37 - janvier 2019 Regresar al número
Artículo precedente Artículo precedente
  • Percutaneous gastric tube placement: Comparison of trans-abdominal and trans-oral approach in patients with chronic ascites
  • A. Gasparetto, M. Rosenberg, D. Hunter, J. Golzarian, D. D'Souza
| Artículo siguiente Artículo siguiente
  • Clinical utility of one month imaging following selective internal radiation therapy
  • S. Young, A. Taylor, J. Golzarian, S. Flanagan, D. D'Souza, T. Sanghvi

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.